查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1555486

亨廷頓氏舞蹈症治療市場，按診斷類型、治療類型、藥物類型、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Huntington's Disease Treatment Market, By Diagnosis Type, By Treatment Type, By Drug Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 284 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年亨丁頓舞蹈症治療市場規模為4.509億美元，2024年至2032年複合年成長率為24.10%。

亨丁頓舞蹈症治療市場-市場動態

亨廷頓病病例的激增以及對治療該疾病的尖端藥物的需求不斷增加預計將推動市場成長

對亨丁頓舞蹈症的了解不斷增加，加上診斷工具的進步，使得早期識別和介入成為可能，從而導致對治療選擇的需求增加。這種大腦退化性疾病影響每 10 萬人中約 3 至 7 人，主要是歐洲血統的人。製藥公司和研究機構正在投入大量資源進行研發，以發現新的治療方案並改善現有療法，從而推動市場的成長。此外，藥物研究的進步為市場擴張提供了更多可能性。然而，發展中地區缺乏認知可能會阻礙市場的進步。

亨廷頓舞蹈症治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 24.10% 左右的複合年成長率成長

根據診斷類型細分，預計診斷成像將在 2023 年顯示最大的市場佔有率

根據治療類型細分，2023年對症治療為主導類型

根據藥物類型細分，丁苯那嗪是 2023 年的主導類型

根據最終用戶細分，醫院藥局是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

亨廷頓舞蹈症治療市場-細分分析：

全球亨廷頓舞蹈症治療市場根據診斷類型、治療類型、藥物類型、最終用戶和地區進行細分。

根據診斷類型，市場分為兩類：診斷影像、基因檢測和其他。診斷成像佔據最大的市場佔有率。由於技術進步提高了診斷、監測和治療效果評估的精確度，亨廷頓舞蹈症治療市場的診斷影像領域正在不斷進步。

根據治療類型，市場分為兩類：症狀治療、疾病緩解治療和其他。對症治療佔市場大部分。症狀治療市場包括一系列旨在控制 HD 各種症狀的方法和治療，例如運動功能障礙、精神症狀和認知能力下降。

根據藥物類型，市場分為兩類：丁苯那嗪、丁苯那嗪和其他藥物。丁苯那嗪佔有最大的市場佔有率。丁苯那嗪主要用於治療舞蹈病，這是亨廷頓舞蹈症的一種常見且致殘的症狀。舞蹈病的特徵是不自主的、突然的運動，會大大影響日常活動和運動。

根據最終用戶，市場分為三類：醫院藥房、零售藥房和線上藥房。醫院藥房是市場的主導部門。他們在藥物管理、配藥、患者護理和治療支持方面發揮著至關重要的作用。

亨廷頓舞蹈症治療市場 - 地理洞察

從地理上看，該市場橫跨北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些區域根據對商業活動有貢獻的國家進一步細分。在疾病緩解療法需求不斷成長的推動下，北美引領市場。該地區擁有多家著名的製藥和生物技術公司，這些公司積極參與亨廷頓病疾病緩解療法的研究和開發。根據國家衛生統計中心的數據，2019年，19.2%的成年人在過去12個月內接受過某種形式的心理健康治療，其中15.8%使用處方藥，9.5%接受心理健康專業人士的諮詢或治療。由於意識的提高和早期診斷，歐洲成為市場成長的第二大地區。

亨廷頓舞蹈症治療市場-競爭格局：

製造商正集中精力在開發疾病緩解療法和創新對症療法方面進行大量研發投資。公司和研究機構正在探索各種方法，例如神經保護劑和先進的基因編輯技術。許多公司正在進行測試新藥和治療策略的臨床試驗，導致下一代 HD 療法的競爭。提供全面的患者支持計劃（包括諮詢和教育）的公司可以透過提高患者的依從性和滿意度來獲得競爭優勢。

最新進展：

A recent interim update on the phase 1/2 trials for uniQure's experimental gene therapy AMT-130 revealed that administering high doses of the treatment led to a notable deceleration of disease advancement and reduction of neurofilament light (NfL) levels in individuals with Huntington's disease (高畫質).

目錄

第1章：亨廷頓舞蹈症治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 亨丁頓舞蹈症治療市場片段（依診斷類型）
    • 亨丁頓舞蹈症治療市場片段（依治療類型）
    • 亨丁頓舞蹈症治療市場片段（依藥物類型）
    • 最終用戶的亨丁頓舞蹈症治療市場片段
    • 亨丁頓舞蹈症治療市場片段（按國家/地區）
    • 按地區分類的亨丁頓舞蹈症治療市場片段
  • 競爭洞察

第 3 章：亨廷頓舞蹈症治療主要市場趨勢

  • 亨丁頓舞蹈症治療市場促進因素
    • 市場促進因素的影響分析
  • 亨丁頓舞蹈症治療市場限制
    • 市場限制影響分析
  • 亨丁頓舞蹈症治療市場機會
  • 亨丁頓舞蹈症治療市場未來趨勢

第 4 章：亨廷頓舞蹈症治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：亨廷頓舞蹈症治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：亨廷頓氏症治療市場格局

  • 亨廷頓舞蹈症治療市場佔有率分析，2023 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：亨廷頓氏症治療市場 - 依診斷類型

  • 概述
    • 按診斷類型分類的細分市場佔有率分析
    • 診斷影像
    • 基因檢測
    • 其他

第 8 章：亨廷頓氏症治療市場 - 按治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 症狀治療
    • 疾病緩解療法
    • 其他

第 9 章：亨廷頓氏症治療市場 - 按藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 丁苯那嗪
    • 丁苯那嗪
    • 其他藥物

第 10 章：亨廷頓舞蹈症治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 11 章：亨廷頓氏症治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美亨廷頓舞蹈症治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按診斷類型）
    • 北美市場規模和預測（按治療類型）
    • 北美市場規模和預測（按藥物類型）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲亨廷頓舞蹈症治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按診斷類型）
    • 歐洲市場規模和預測（按治療類型）
    • 歐洲市場規模和預測（按藥物類型）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區亨廷頓舞蹈症治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按診斷類型）
    • 亞太地區市場規模與預測（按治療類型）
    • 亞太地區市場規模和預測（按藥物類型）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲亨廷頓舞蹈症治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模和預測（按診斷類型）
    • 拉丁美洲市場規模與預測（按治療類型）
    • 拉丁美洲市場規模與預測（按藥物類型）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲亨廷頓氏舞蹈症治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按診斷類型）
    • 中東和非洲市場規模及預測（按治療類型）
    • 中東和非洲市場規模及預測（按藥物類型）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 亨廷頓舞蹈症治療產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • Alnylam Pharmaceuticals Inc.
    • Ceregene Inc.
    • Prana Biotechnology Limited
    • Teva Pharmaceutical Industries Ltd
    • Ionis Pharmaceuticals
    • Neurocrine Biosciences Inc.
    • Prilenia Therapeutics
    • Azevan Pharmaceuticals
    • Lundbeck
    • PTC Therapeutics
    • UniQure
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3593

REPORT HIGHLIGHT

Huntington's Disease Treatment Market size was valued at USD 450.90 million in 2023, expanding at a CAGR of 24.10% from 2024 to 2032.

Huntington's disease is a rare genetic disorder that currently has no cure and causes the deterioration of brain cells. Early signs often include problems with coordination and occasional memory lapses. This disease has a significant impact on a person's motor skills, cognitive functions, and overall mental health. The rarity of Huntington's disease is notable, as it is usually passed down through a mutated gene from one of the parents. The disorder mainly results in a range of movement difficulties, as well as mental health challenges and issues with cognitive processes like planning and reasoning. According to the Genetic and Rare Diseases Information Center (GARD), there are fewer than 5,000 individuals in the United States living with Huntington's disease.

Huntington's Disease Treatment Market- Market Dynamics

The surge in Huntington's disease cases and the escalating requirement for cutting-edge drugs to address the disease are projected to fuel market growth

Increased knowledge about Huntington's disease, along with advancements in diagnostic tools, is enabling early identification and intervention, leading to a rise in the need for treatment choices. This degenerative brain condition affects around 3 to 7 people per 100,000, mainly in individuals of European ancestry. Pharmaceutical companies and research institutions are dedicating significant resources to research and development to discover new treatment options and improve existing therapies, thereby fueling the growth of the market. Furthermore, advancements in drug research offer additional possibilities for market expansion. However, a lack of awareness in developing areas could impede the progress of the market.

Huntington's Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 24.10% over the forecast period (2024-2032)

Based on Diagnosis Type segmentation, Diagnostic Imaging was predicted to show maximum market share in the year 2023

Based on Treatment Type segmentation, Symptomatic Therapy was the leading type in 2023

Based on Drug Type segmentation, Tetrabenazine was the leading type in 2023

Based on End-User segmentation, Hospital Pharmacies was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Huntington's Disease Treatment Market- Segmentation Analysis:

The Global Huntington's Disease Treatment Market is segmented based on Diagnosis Type, Treatment Type, Drug Type, End-User, and Region.

The market is categorized into two groups according to Diagnosis Type: Diagnostic Imaging, Genetic Testing, and Others. Diagnostic Imaging holds the largest share of the market. The diagnostic imaging sector of Huntington's disease Treatment Market is progressing due to technological advancements that enhance the precision of diagnosis, monitoring, and assessment of treatment effectiveness.

The market is segmented into two categories according to Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, and Others. Symptomatic Therapy holds the majority share in the market. The market for symptomatic therapy treatment encompasses a range of methods and treatments aimed at managing the various symptoms of HD, such as motor dysfunction, psychiatric symptoms, and cognitive decline.

The market is segmented into two groups according to Drug Type: Tetrabenazine, Deutetrabenazine, and Other Drugs. Tetrabenazine holds the largest share of the market. Tetrabenazine is mainly prescribed for the treatment of chorea, a prevalent and disabling symptom of Huntington's disease. Chorea is characterized by involuntary, abrupt movements that can greatly affect everyday activities and movement.

The market is segmented into three categories according to End-User: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are the leading sector in the market. They play a vital role in medication management, dispensing, patient care, and treatment support.

Huntington's Disease Treatment Market- Geographical Insights

Geographically, this market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented by countries contributing to business activities. North America leads the market, driven by the increasing demand for disease-modifying therapies. This region is home to several prominent pharmaceutical and biotechnology companies actively involved in the research and development of disease-modifying therapies for Huntington's disease. According to the National Center for Health Statistics, in 2019, 19.2% of adults had received some form of mental health treatment in the past 12 months, with 15.8% using prescription medication and 9.5% receiving counseling or therapy from a mental health professional. Europe is the second-largest region for market growth, attributed to rising awareness and early diagnosis.

Huntington's Disease Treatment Market- Competitive Landscape:

Manufacturers are concentrating on making significant R&D investments in the development of disease-modifying treatments and innovative symptomatic therapies. Various approaches, such as neuroprotective agents and advanced gene-editing techniques, are being explored by companies and research institutions. Clinical trials to test new drugs and treatment strategies are being conducted by many companies, leading to competition in the advancement of the next generation of HD therapies. Companies that provide comprehensive patient support programs, including counseling and education, may gain a competitive advantage by improving patient adherence and satisfaction.

Recent Developments:

A recent interim update on the phase 1/2 trials for uniQure's experimental gene therapy AMT-130 revealed that administering high doses of the treatment led to a notable deceleration of disease advancement and reduction of neurofilament light (NfL) levels in individuals with Huntington's disease (HD).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ceregene Inc.
  • Prana Biotechnology Limited
  • Teva Pharmaceutical Industries Ltd
  • Ionis Pharmaceuticals
  • Neurocrine Biosciences Inc.
  • Prilenia Therapeutics
  • Azevan Pharmaceuticals
  • Lundbeck
  • PTC Therapeutics
  • UniQure
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DIAGNOSIS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Imaging
  • Genetic Testing
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Symptomatic Therapy
  • Disease-Modifying Therapy
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Tetrabenazine
  • Deutetrabenazine
  • Other Drugs

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Huntington's Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Huntington's Disease Treatment Market Snippet by Diagnosis Type
    • 2.1.2. Huntington's Disease Treatment Market Snippet by Treatment Type
    • 2.1.3. Huntington's Disease Treatment Market Snippet by Drug Type
    • 2.1.4. Huntington's Disease Treatment Market Snippet by End-User
    • 2.1.5. Huntington's Disease Treatment Market Snippet by Country
    • 2.1.6. Huntington's Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Huntington's Disease Treatment Key Market Trends

  • 3.1. Huntington's Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Huntington's Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Huntington's Disease Treatment Market Opportunities
  • 3.4. Huntington's Disease Treatment Market Future Trends

4. Huntington's Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Huntington's Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Huntington's Disease Treatment Market Landscape

  • 6.1. Huntington's Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Huntington's Disease Treatment Market - By Diagnosis Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnosis Type, 2023 & 2032 (%)
    • 7.1.2. Diagnostic Imaging
    • 7.1.3. Genetic Testing
    • 7.1.4. Others

8. Huntington's Disease Treatment Market - By Treatment Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 8.1.2. Symptomatic Therapy
    • 8.1.3. Disease-Modifying Therapy
    • 8.1.4. Others

9. Huntington's Disease Treatment Market - By Drug Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 9.1.2. Tetrabenazine
    • 9.1.3. Deutetrabenazine
    • 9.1.4. Other Drugs

10. Huntington's Disease Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Huntington's Disease Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Huntington's Disease Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Huntington's Disease Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Huntington's Disease Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Huntington's Disease Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Huntington's Disease Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Huntington's Disease Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. Alnylam Pharmaceuticals Inc.
    • 12.2.3. Ceregene Inc.
    • 12.2.4. Prana Biotechnology Limited
    • 12.2.5. Teva Pharmaceutical Industries Ltd
    • 12.2.6. Ionis Pharmaceuticals
    • 12.2.7. Neurocrine Biosciences Inc.
    • 12.2.8. Prilenia Therapeutics
    • 12.2.9. Azevan Pharmaceuticals
    • 12.2.10. Lundbeck
    • 12.2.11. PTC Therapeutics
    • 12.2.12. UniQure
    • 12.2.13. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us